Latest News

Treatment initiation with a higher-efficacy DMT: update from AAN


Focus on ofatumumab

There is a growing body of evidence supporting the use of high-efficacy disease-modifying therapies (DMT) as first-line agents in the treatment of multiple sclerosis. Since the TRANSFORMS trial over a decade ago, numerous pivotal trials have demonstrated the superiority of higher-efficacy DMTs over lower-efficacy agents (Cohen et al. N Engl J Med 2010;362:402-415). The concern with this more aggressive approach was safety. However, the accumulation of long-term safety data, most notably for anti-CD20 agents, has demonstrated the low risk of serious adverse events with sustained exposure to selected high-efficacy DMTs in clinical practice. Read More